Primary Biliary Cholangitis News and Research

RSS

More data, more answers? A 1.9 million-person health study shows why scale has limits

Researchers analyzed phenotypic and linked health-record data from more than 1.9 million adults in Our Future Health, comparing demographic characteristics, disease patterns, clinical associations, and rare-condition case counts with national data and other major cohorts. The cohort's size provides unusually large samples for many common and less common conditions, although its demographic composition and current data sources require careful consideration when interpreting population-level estimates.

14 Sep 2026

Autoimmune diseases form distinct genetic clusters, study finds

Different autoimmune diseases often share genetic risk factors, but not through a single common genetic vulnerability.

4 Sep 2026

PCORI funding awarded to study symptom management for rare cholestatic liver diseases

The Patient-Centered Outcomes Research Institute (PCORI) has announced a $13 million funding award to the University of North Carolina at Chapel Hill over five years to study innovative symptom management interventions for patients with rare cholestatic liver diseases.

1 Sep 2026

Digital program reduces anxiety and depression in adults with chronic medical conditions

A digital program combining guided movement, breathing and meditation exercises, and coping-skills training reduced anxiety and depression symptoms in adults with chronic medical conditions, according to a new study published August 20th in the open access journal PLOS Medicine by Puneeta Tandon of the University of Alberta, Canada, and colleagues.

20 Aug 2026

Emerging PPAR therapies offer new hope for primary biliary cholangitis

Primary biliary cholangitis is a rare autoimmune disease that affects the liver and can progress to cirrhosis. It occurs when the immune system attacks the small bile ducts within the liver. As a result, bile builds up, leading to inflammation and progressive liver damage. Although a first-line treatment exists, 40% of patients do not respond adequately to it or cannot tolerate it, so new treatment options need to be developed.

23 Jul 2026

Biliary epithelial cells found to actively prevent liver fibrosis development

Many liver diseases share a common characteristic: fibrosis, that is, the progressive accumulation of scarring in the liver tissue.

28 Apr 2026

Blood group A linked to a higher risk of primary biliary cholangitis

Findings indicate blood group A elevates the risk of primary biliary cholangitis, suggesting ABO group analysis could aid in autoimmune liver disease diagnosis.

19 Nov 2025

Understanding thrombocytopenia in patients with portal hypertension and chronic liver disease

Chronic liver disease (CLD) and its advanced stage, cirrhosis, represent a significant global health burden, with portal hypertension (PH) being a primary driver of disease progression and decompensation.

12 Nov 2025

New study identifies potential target for treating diabetic cardiomyopathy

Some patients with diabetes develop a serious condition known as diabetic cardiomyopathy, which is slow and cannot be directly attributed to hypertension or other cardiovascular disorders.

12 Dec 2024

Review highlights mitochondrial dysfunction in cholestatic liver injury

Bile acids are essential signaling molecules derived from cholesterol metabolism in the liver and are crucial for the digestion and absorption of fats.

16 Sep 2024

Elevated pressure in the bile canaliculi alters structure of the liver tissue

The liver produces bile, which the intestine uses for digestion. For the transport of bile, the liver relies on a network of microscopic tubings, known as bile canaliculi, formed by liver cells called hepatocytes.

7 Sep 2023

Study shows that anti-PTM antibodies are often present in autoimmune mediated liver disease

A recent study published in Frontiers in Medicine described anti-post-translational modification (PTM) antibodies in patients with autoimmune-mediated and cholestatic liver diseases (AILD).

31 Jul 2023

Study provide new insights into why cholestasis causes cognitive issues

Patients with cholestatic liver disease such as primary biliary cholangitis (PBC) can experience significant impairment of bile flow and may develop neurological symptoms including fatigue and cognitive decline.

6 Dec 2022

Report highlights the need for an office to support autoimmune disease research across NIH institutes

While the quantity and quality of research that the National Institutes of Health (NIH) conducts on autoimmune diseases is impressive, a strategic plan and a well-funded office to support the coordination of all autoimmune disease research across NIH institutes and centers are needed, says a new congressionally mandated report from the National Academies of Sciences, Engineering, and Medicine.

10 May 2022

Researchers identify a novel host-directed therapeutic approach to COVID-19

Researchers in the UK have demonstrated the potential of modulating the expression of angiotensin-converting enzyme 2 (ACE2) as a novel host-directed therapeutic approach to protecting against coronavirus disease 2019 (COVID-19).

8 Jun 2021

Devastating liver disease itching turns out to have a surprising cause

A devastating itching of the skin driven by severe liver disease turns out to have a surprising cause. Its discovery points toward possible new therapies for itching, and shows that the outer layer of the skin is so much more than insulation.

5 Apr 2021

Scientists identify key cell signaling pathway that drives muscle loss

Researchers at the University of Nebraska Medical Center have identified a key cell signaling pathway that drives the devastating muscle loss, or cachexia, suffered by many cancer patients.

22 May 2020

60+ organizations to speak as the NASH Summit Boston returns

Hansonwade will present the 4th NASH Summit in Boston from May 4-7, 2020. For its anticipated return, the forum is set to widen its program and congregate over 350+ industry stakeholders for presentations from global regulatory agencies and leading biopharma.

From 4th NASH Summit Boston 29 Jan 2020

Trial shows nor-urso as an effective treatment option for nonalcoholic fatty liver disease

A team led by Michael Trauner at MedUni Vienna's Division of Gastroenterology and Hepatology demonstrated the beneficial effect of synthetically produced bile acid with the active agent nor-ursodeoxycholic acid (nor-urso) in the hitherto incurable liver disease primary sclerosing cholangitis (PSC) around two years ago.

29 Jul 2019

Liquorice tea linked to hypertensive emergency – a case report

An 84-year-old man was admitted with hypertensive (high blood pressure) emergency after consuming a large amount of licorice tea.

28 May 2019